Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
131.20
+0.48 (+0.37%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
McDonald's Revenues Expected To Increase, Plus Merck And More On CNBC's 'Final Trades'
January 04, 2024
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners named Merck & Co., Inc. (NYSE: MRK)
Via
Benzinga
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
January 04, 2024
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...
Via
Benzinga
Topics
ETFs
AMD To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Thursday
January 04, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Revenge of the Boring Stocks! Dividends Are Sexy Again.
January 03, 2024
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now.
Via
InvestorPlace
What the Options Market Tells Us About Merck & Co
December 26, 2023
Via
Benzinga
Looking Into Merck & Co's Recent Short Interest
December 25, 2023
Via
Benzinga
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth
January 03, 2024
U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC.
Via
Benzinga
Topics
ETFs
10 Health Care Stocks Whale Activity In Today's Session
January 02, 2024
Via
Benzinga
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
December 29, 2023
There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?
December 29, 2023
The pair's collaboration is making waves, and there's more to come.
Via
The Motley Fool
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
Common Investing Mistake: Income Obsession (& More)
December 28, 2023
A common investing mistake is income obsession. Others are holding too many stocks and focusing on valuation to know if the price of a stock is right. Sounds familiar? Any of these mistakes hurts your...
Via
Talk Markets
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
January Effect: 3 Under-the-Radar Stocks Poised for a New Year Jump
December 24, 2023
Are you looking to profit from the January effect? Here are three under-the-radar stocks poised for a new year's jump.
Via
InvestorPlace
7 Small-Cap Stocks That Wall Street Loves for Good Reason
December 22, 2023
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading
Via
InvestorPlace
7 Best Dow Jones Stocks to Buy for Conservative Investors
December 21, 2023
With many vagaries still surrounding the market, the best Dow Jones stocks for conservative investors offers a safer approach.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
December 21, 2023
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or...
Via
Benzinga
Exposures
Product Safety
Better Dividend Stock: Bristol Myers Squibb or Merck?
December 19, 2023
These two pharma stocks have sizable dividend yields. Which is the better buy right now?
Via
The Motley Fool
Jim Cramer Slams FTC Chair Lina Khan's Policies For Hampering Investor Returns: 'One-Woman Wrecking Crew For Your Stock Portfolio'
December 18, 2023
He posits that such actions have negatively impacted stock valuations.
Via
Benzinga
3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024
December 18, 2023
Analysts think these beaten-down stocks could rebound strongly in the new year.
Via
The Motley Fool
Moderna Just Took a Step Closer to Its Product Launch Goal. Is the Stock a Buy?
December 18, 2023
Moderna's personalized cancer vaccine candidate just delivered excellent clinical trial results.
Via
The Motley Fool
Contaminated Vaccines: FDA Reportedly Finds Cleaning And Expiry Lapses At Moderna's Massachusetts Facility
December 16, 2023
The U.S. Food and Drug Administration (FDA) identified several quality control issues at the primary manufacturing facility of Moderna Inc. (NASDAQ: MRNA)
Via
Benzinga
Exposures
Product Safety
What's Going On With C4 Therapeutics Stock?
December 15, 2023
C4 Therapeutics, Inc. (NASDAQ: CCCC) shares are trading higher Friday, and the stock has gained more than 350% over the past five days.
Via
Benzinga
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients
December 15, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a...
Via
Benzinga
Exposures
Product Safety
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
December 14, 2023
Moderna is in focus after reporting positive results for its cancer treatment today, with MRNA stock surging more than 9%.
Via
InvestorPlace
Moderna CEO Highlights Promising Cancer Vaccine Data: 'Think About The Number Of Lives That Can Be Impacted'
December 14, 2023
Moderna, Inc. (NASDAQ: MRNA) CEO Stéphane Bancel appeared on CNBC's "Squawk Box" Thursday to discuss the company's promising new cancer vaccine developed in
Via
Benzinga
Why Is Moderna (MRNA) Stock Up 11% Today?
December 14, 2023
Moderna stock is on the rise Thursday as investors in MRNA react to positive results from a skin cancer vaccine in a Phase 2b trial.
Via
InvestorPlace
Moderna Stock Is Soaring Today - Here's Why
December 14, 2023
Moderna Inc (NASDAQ: MRNA) and Merck & Co Inc (NYSE: MRK) announced follow-up data from the Phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940), an investigational individualized...
Via
Benzinga
Moderna's Cancer Vaccine Cuts Risk Of Relapse, Death By 49%; Will Shares Jump?
December 14, 2023
Moderna and Merck are already working on a Phase 3 study, but these are long-running tests.
Via
Investor's Business Daily
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
December 14, 2023
Pfizer recently outlined expectations for 2024 results in light of an upcoming $43 billion acquisition of Seagen.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.